Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells

Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells

Multiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins. The high rate of synthesis makes myeloma cells dependent on protein processing mechanisms related to the...

Full description

Bibliographic Details
Main Authors:	Marta Pelon, Patryk Krzeminski, Zuzanna Tracz-Gaszewska, Irena Misiewicz-Krzeminska
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Pharmacology
Subjects:	proteasome proteasome inhibitors bortezomib carfilzomib multiple myeloma
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1351565/full

Similar Items

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
by: John H. Chen, et al.
Published: (2017-06-01)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
by: Maiko Matsushita, et al.
Published: (2023-09-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
by: Diego Acosta-Alvear, et al.
Published: (2015-09-01)

Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01)

The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
by: Chun-fung Sin, et al.
Published: (2021-12-01)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
by: Shansa Pranami E. Jayaweera, et al.
Published: (2021-11-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

The role of proteasomes in tumorigenesis
by: Xiangyi Zhou, et al.
Published: (2024-07-01)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
by: Carol Chen-Scarabelli, et al.
Published: (2017-07-01)

Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?
by: Giuseppe Fanciulli, et al.
Published: (2023-04-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014-12-01)

Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma
by: Francesca Alessandra Ambrosio, et al.
Published: (2023-02-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity
by: Callan D. Wesley, et al.
Published: (2024-10-01)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure
by: David S. Pitcher, et al.
Published: (2015-07-01)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
by: Yuka Kawaji‐Kanayama, et al.
Published: (2022-02-01)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
by: Mariah L. Farrell, et al.
Published: (2018-05-01)

Experimental Study on the Mechanism of Reversal of Leukemia Multidrug Resistance by Proteasome Inhibitor Bortezomib
by: Ying-chun LI, et al.
Published: (2010-08-01)

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications
by: Mohammad Alwahsh, et al.
Published: (2023-01-01)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
by: Jonas Schwestermann, et al.
Published: (2022-05-01)

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
by: Marcelle G. Meseeha, et al.
Published: (2015-12-01)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
by: Paul G. Richardson, et al.
Published: (2020-07-01)

Unexpected hope for a multiple myeloma patient
by: Minodora Cezarina Onisâi, et al.
Published: (2020-10-01)

Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents
by: Carlos R. Viera, et al.
Published: (2022-09-01)

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
by: Azam Salimi, et al.
Published: (2022-07-01)

Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis
by: Marwa Tantawy, et al.
Published: (2021-04-01)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
by: Min Seung Lee, et al.
Published: (2021-02-01)

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
by: Pan Su, et al.
Published: (2022-05-01)

Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors
by: Angel Chao, et al.
Published: (2016-02-01)

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System
by: Syeda A. Mina, et al.
Published: (2021-08-01)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
by: Jielin Li, et al.
Published: (2021-05-01)

Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review
by: Xin-xin Yang, et al.
Published: (2024-08-01)

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
by: Grazia Raffaella Tundo, et al.
Published: (2022-02-01)

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
by: Eva Plakoula, et al.
Published: (2025-01-01)

Identification of KDM4C as a gene conferring drug resistance in multiple myeloma
by: Zhang Na, et al.
Published: (2024-04-01)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)

Toll-like receptor signaling in multiple myeloma cells promotes the expression of pro-survival genes B-cell lymphoma 2 and MYC and modulates the expression of B-cell maturation antigen
by: Synne Stokke Tryggestad, et al.
Published: (2024-06-01)